Trial Outcomes & Findings for A Single Rising Dose Study of MK-8150 (MK-8150-001) (NCT NCT01590810)

Last Updated: 2018-09-25

Results Overview

An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the study drug. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the study drug, is also an AE.

Recruitment status

COMPLETED

Study phase

PHASE1

Target enrollment

34 participants

Primary outcome timeframe

Up to 14 days after the last dose (Up to approximately 42 days)

Results posted on

2018-09-25

Participant Flow

Participant milestones

Participant milestones
Measure	Panel A - MK-8150 2 to 90 mg/Placebo Within each of the up to 5 treatment periods in Panel A, 6 healthy participants were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel A was 2 mg to 90 mg.	Panel B - MK-8150 4 to 120 mg/Placebo Within each of the up to 5 treatment periods in Panel B, 6 healthy participants were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel B was 4 mg to 120 mg.	Panel C - MK-8150 5 to 90 mg/Placebo Within each of the up to 5 treatment periods in Panel C, 6 participants with mild to moderate hypertension were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel C was 5 mg to 90 mg.	Panel D - MK-8150 50 to 200 mg Description: Within Panel D, 8 healthy participants were randomly assigned to receive single doses of MK-8150, and 2 were randomly assigned to receive single administrations of matching placebo throughout the up to 5 treatment periods according to a computer-generated allocation schedule (i.e., assignment of a participant to either MK-8150 or placebo was fixed for all Panel D periods). This reporting group presents data for the Panel D participants administered MK-8150. The dose range of MK-8150 administered for Panel D was 50 mg to 200 mg.	Panel D - Placebo Within Panel D, 8 healthy participants were randomly assigned to receive single doses of MK-8150, and 2 were randomly assigned to receive single administrations of matching placebo throughout the up to 5 treatment periods according to a computer-generated allocation schedule (i.e., assignment of a participant to either MK-8150 or placebo was fixed for all Panel D periods). This reporting group presents data for the Panel D participants administered placebo.
Overall Study STARTED	8	8	8	8	2
Overall Study COMPLETED	8	7	7	8	2
Overall Study NOT COMPLETED	0	1	1	0	0

Reasons for withdrawal

Reasons for withdrawal
Measure	Panel A - MK-8150 2 to 90 mg/Placebo Within each of the up to 5 treatment periods in Panel A, 6 healthy participants were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel A was 2 mg to 90 mg.	Panel B - MK-8150 4 to 120 mg/Placebo Within each of the up to 5 treatment periods in Panel B, 6 healthy participants were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel B was 4 mg to 120 mg.	Panel C - MK-8150 5 to 90 mg/Placebo Within each of the up to 5 treatment periods in Panel C, 6 participants with mild to moderate hypertension were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel C was 5 mg to 90 mg.	Panel D - MK-8150 50 to 200 mg Description: Within Panel D, 8 healthy participants were randomly assigned to receive single doses of MK-8150, and 2 were randomly assigned to receive single administrations of matching placebo throughout the up to 5 treatment periods according to a computer-generated allocation schedule (i.e., assignment of a participant to either MK-8150 or placebo was fixed for all Panel D periods). This reporting group presents data for the Panel D participants administered MK-8150. The dose range of MK-8150 administered for Panel D was 50 mg to 200 mg.	Panel D - Placebo Within Panel D, 8 healthy participants were randomly assigned to receive single doses of MK-8150, and 2 were randomly assigned to receive single administrations of matching placebo throughout the up to 5 treatment periods according to a computer-generated allocation schedule (i.e., assignment of a participant to either MK-8150 or placebo was fixed for all Panel D periods). This reporting group presents data for the Panel D participants administered placebo.
Overall Study Physician Decision	0	1	1	0	0

Baseline Characteristics

A Single Rising Dose Study of MK-8150 (MK-8150-001)

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Panel A - MK-8150 2 to 90 mg/Placebo n=8 Participants Within each of the up to 5 treatment periods in Panel A, 6 healthy participants were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel A was 2 mg to 90 mg.	Panel B - MK-8150 4 to 120 mg/Placebo n=8 Participants Within each of the up to 5 treatment periods in Panel B, 6 healthy participants were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel B was 4 mg to 120 mg.	Panel C - MK-8150 5 to 90 mg/Placebo n=8 Participants Within each of the up to 5 treatment periods in Panel C, 6 participants with mild to moderate hypertension were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel C was 5 mg to 90 mg.	Panel D - MK-8150 50 to 200 mg n=8 Participants Description: Within Panel D, 8 healthy participants were randomly assigned to receive single doses of MK-8150, and 2 were randomly assigned to receive single administrations of matching placebo throughout the up to 5 treatment periods according to a computer-generated allocation schedule (i.e., assignment of a participant to either MK-8150 or placebo was fixed for all Panel D periods). This reporting group presents data for the Panel D participants administered MK-8150. The dose range of MK-8150 administered for Panel D was 50 mg to 200 mg.	Panel D - Placebo n=2 Participants Within Panel D, 8 healthy participants were randomly assigned to receive single doses of MK-8150, and 2 were randomly assigned to receive single administrations of matching placebo throughout the up to 5 treatment periods according to a computer-generated allocation schedule (i.e., assignment of a participant to either MK-8150 or placebo was fixed for all Panel D periods). This reporting group presents data for the Panel D participants administered placebo.	Total n=34 Participants Total of all reporting groups
Age, Continuous	37.5 years STANDARD_DEVIATION 9.8 • n=5 Participants	34.8 years STANDARD_DEVIATION 8.0 • n=7 Participants	51.4 years STANDARD_DEVIATION 6.8 • n=5 Participants	44.1 years STANDARD_DEVIATION 6.9 • n=4 Participants	39.0 years STANDARD_DEVIATION 12.7 • n=21 Participants	42 years STANDARD_DEVIATION 10 • n=10 Participants
Sex: Female, Male Female	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants
Sex: Female, Male Male	8 Participants n=5 Participants	8 Participants n=7 Participants	8 Participants n=5 Participants	8 Participants n=4 Participants	2 Participants n=21 Participants	34 Participants n=10 Participants
Central Systolic Blood Pressure (cSBP)	98 mm Hg STANDARD_DEVIATION 7 • n=5 Participants	98 mm Hg STANDARD_DEVIATION 6 • n=7 Participants	125 mm Hg STANDARD_DEVIATION 8 • n=5 Participants	102 mm Hg STANDARD_DEVIATION 9 • n=4 Participants	105 mm Hg STANDARD_DEVIATION 6 • n=21 Participants	106 mm Hg STANDARD_DEVIATION 13 • n=10 Participants
Augmentation Index (AIx)	7 percentage of central pulse pressure STANDARD_DEVIATION 3 • n=5 Participants	8 percentage of central pulse pressure STANDARD_DEVIATION 4 • n=7 Participants	22 percentage of central pulse pressure STANDARD_DEVIATION 8 • n=5 Participants	10 percentage of central pulse pressure STANDARD_DEVIATION 11 • n=4 Participants	8 percentage of central pulse pressure STANDARD_DEVIATION 12 • n=21 Participants	12 percentage of central pulse pressure STANDARD_DEVIATION 9 • n=10 Participants
Heart Rate (HR)	58 beats per minute STANDARD_DEVIATION 7 • n=5 Participants	54 beats per minute STANDARD_DEVIATION 5 • n=7 Participants	67 beats per minute STANDARD_DEVIATION 9 • n=5 Participants	61 beats per minute STANDARD_DEVIATION 7 • n=4 Participants	45 beats per minute STANDARD_DEVIATION 1 • n=21 Participants	59 beats per minute STANDARD_DEVIATION 9 • n=10 Participants
Central Diastolic Blood Pressure (cDBP)	85 mm Hg STANDARD_DEVIATION 6 • n=5 Participants	84 mm Hg STANDARD_DEVIATION 6 • n=7 Participants	107 mm Hg STANDARD_DEVIATION 6 • n=5 Participants	86 mm Hg STANDARD_DEVIATION 8 • n=4 Participants	91 mm Hg STANDARD_DEVIATION 6 • n=21 Participants	91 mm Hg STANDARD_DEVIATION 11 • n=10 Participants
Peripheral Systolic Blood Pressure (pSBP)	119 mm Hg STANDARD_DEVIATION 5 • n=5 Participants	119 mm Hg STANDARD_DEVIATION 6 • n=7 Participants	148 mm Hg STANDARD_DEVIATION 7 • n=5 Participants	125 mm Hg STANDARD_DEVIATION 8 • n=4 Participants	126 mm Hg STANDARD_DEVIATION 12 • n=21 Participants	128 mm Hg STANDARD_DEVIATION 14 • n=10 Participants
Peripheral Diastolic Blood Pressure (pDBP)	75 mm Hg STANDARD_DEVIATION 6 • n=5 Participants	73 mm Hg STANDARD_DEVIATION 6 • n=7 Participants	94 mm Hg STANDARD_DEVIATION 6 • n=5 Participants	75 mm Hg STANDARD_DEVIATION 8 • n=4 Participants	80 mm Hg STANDARD_DEVIATION 7 • n=21 Participants	79 mm Hg STANDARD_DEVIATION 10 • n=10 Participants

PRIMARY outcome

Timeframe: Up to 14 days after the last dose (Up to approximately 42 days)

Population: All participants who received a dose of study drug

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 2 to 90 mg/Placebo n=8 Participants Within each of the up to 5 treatment periods in Panel A, 6 healthy participants were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel A was 2 mg to 90 mg.	Panel B - MK-8150 4 to 120 mg/Placebo n=8 Participants Within each of the up to 5 treatment periods in Panel B, 6 healthy participants were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel B was 4 mg to 120 mg.	Panel C - MK-8150 5 to 90 mg/Placebo n=8 Participants Within each of the up to 5 treatment periods in Panel C, 6 participants with mild to moderate hypertension were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel C was 5 mg to 90 mg.	Panel D - MK-8150 50 to 200 mg n=8 Participants Description: Within Panel D, 8 healthy participants were randomly assigned to receive single doses of MK-8150, and 2 were randomly assigned to receive single administrations of matching placebo throughout the up to 5 treatment periods according to a computer-generated allocation schedule (i.e., assignment of a participant to either MK-8150 or placebo was fixed for all Panel D periods). This reporting group presents data for the Panel D participants administered MK-8150. The dose range of MK-8150 administered for Panel D was 50 mg to 200 mg.	Panel D - Placebo n=2 Participants Within Panel D, 8 healthy participants were randomly assigned to receive single doses of MK-8150, and 2 were randomly assigned to receive single administrations of matching placebo throughout the up to 5 treatment periods according to a computer-generated allocation schedule (i.e., assignment of a participant to either MK-8150 or placebo was fixed for all Panel D periods). This reporting group presents data for the Panel D participants administered placebo.	Panel A - Placebo Single dose of placebo
Number of Participants With an Adverse Event (AE)	8 participants	8 participants	7 participants	7 participants	2 participants	—

PRIMARY outcome

Timeframe: Up to 14 days after the last dose (Up to approximately 42 days)

Population: All participants who received a dose of study drug

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 2 to 90 mg/Placebo n=8 Participants Within each of the up to 5 treatment periods in Panel A, 6 healthy participants were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel A was 2 mg to 90 mg.	Panel B - MK-8150 4 to 120 mg/Placebo n=8 Participants Within each of the up to 5 treatment periods in Panel B, 6 healthy participants were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel B was 4 mg to 120 mg.	Panel C - MK-8150 5 to 90 mg/Placebo n=8 Participants Within each of the up to 5 treatment periods in Panel C, 6 participants with mild to moderate hypertension were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel C was 5 mg to 90 mg.	Panel D - MK-8150 50 to 200 mg n=8 Participants Description: Within Panel D, 8 healthy participants were randomly assigned to receive single doses of MK-8150, and 2 were randomly assigned to receive single administrations of matching placebo throughout the up to 5 treatment periods according to a computer-generated allocation schedule (i.e., assignment of a participant to either MK-8150 or placebo was fixed for all Panel D periods). This reporting group presents data for the Panel D participants administered MK-8150. The dose range of MK-8150 administered for Panel D was 50 mg to 200 mg.	Panel D - Placebo n=2 Participants Within Panel D, 8 healthy participants were randomly assigned to receive single doses of MK-8150, and 2 were randomly assigned to receive single administrations of matching placebo throughout the up to 5 treatment periods according to a computer-generated allocation schedule (i.e., assignment of a participant to either MK-8150 or placebo was fixed for all Panel D periods). This reporting group presents data for the Panel D participants administered placebo.	Panel A - Placebo Single dose of placebo
Number of Participants Who Discontinued Study Due to an AE	0 participants	0 participants	0 participants	0 participants	0 participants	—

PRIMARY outcome

Timeframe: Pre-dose and 2, 3, 4, 6, 8, 12, 16 and 24 hours post dose

Population: Per-Protocol population. 2 participants received placebo in period of fasted administration of MK-8150 24 mg dose and again received placebo during the period of fed administration of that dose. Data for both administrations of placebo in these participants are included (i.e., for placebo, analysis includes 10 observations from 8 participants)

cSBP was measured by applanation tonometry of the radial artery, using the SphygmoCor System. The central pressure waveform was determined from the peripheral pressure waveform by a transfer function. Time-weighted average was obtained as follows: For all cSBP values obtained over the 24-hour observation period, multiply the length of time that the participant spent at each cSBP value by that cSBP value, add these products together, and then divide by duration of the observation period. The length of time spent at an identified cSBP value was defined as the time elapsed since previous post-dose measurement, or time elapsed since drug administration, if there is no previous post-dose measurement.

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 2 to 90 mg/Placebo n=6 Participants Within each of the up to 5 treatment periods in Panel A, 6 healthy participants were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel A was 2 mg to 90 mg.	Panel B - MK-8150 4 to 120 mg/Placebo n=6 Participants Within each of the up to 5 treatment periods in Panel B, 6 healthy participants were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel B was 4 mg to 120 mg.	Panel C - MK-8150 5 to 90 mg/Placebo n=6 Participants Within each of the up to 5 treatment periods in Panel C, 6 participants with mild to moderate hypertension were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel C was 5 mg to 90 mg.	Panel D - MK-8150 50 to 200 mg n=6 Participants Description: Within Panel D, 8 healthy participants were randomly assigned to receive single doses of MK-8150, and 2 were randomly assigned to receive single administrations of matching placebo throughout the up to 5 treatment periods according to a computer-generated allocation schedule (i.e., assignment of a participant to either MK-8150 or placebo was fixed for all Panel D periods). This reporting group presents data for the Panel D participants administered MK-8150. The dose range of MK-8150 administered for Panel D was 50 mg to 200 mg.	Panel D - Placebo n=6 Participants Within Panel D, 8 healthy participants were randomly assigned to receive single doses of MK-8150, and 2 were randomly assigned to receive single administrations of matching placebo throughout the up to 5 treatment periods according to a computer-generated allocation schedule (i.e., assignment of a participant to either MK-8150 or placebo was fixed for all Panel D periods). This reporting group presents data for the Panel D participants administered placebo.	Panel A - Placebo n=8 Participants Single dose of placebo
Change From Baseline in Time-weighted Average Across 24 Hours (TWA0-24hrs) cSBP in Healthy Male Participants Administered Single Doses of MK-8150 and Placebo (Panel A)	1.33 mm Hg Standard Error 0.99	-1.65 mm Hg Standard Error 1.31	-7.69 mm Hg Standard Error 1.71	-6.29 mm Hg Standard Error 1.82	-9.86 mm Hg Standard Error 1.66	0.55 mm Hg Standard Error 1.08

PRIMARY outcome

Timeframe: Pre-dose and 2, 3, 4, 6, 8, 12, 16 and 24 hours post dose

Population: Per-Protocol population. 2 participants received placebo in period of initial administration of MK-8150 120 mg dose and again received placebo during the period of repeat administration of that dose. Data for both administrations of placebo in these participants are included (i.e., for placebo, analysis includes 10 observations from 8 participants)

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 2 to 90 mg/Placebo n=6 Participants Within each of the up to 5 treatment periods in Panel A, 6 healthy participants were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel A was 2 mg to 90 mg.	Panel B - MK-8150 4 to 120 mg/Placebo n=6 Participants Within each of the up to 5 treatment periods in Panel B, 6 healthy participants were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel B was 4 mg to 120 mg.	Panel C - MK-8150 5 to 90 mg/Placebo n=6 Participants Within each of the up to 5 treatment periods in Panel C, 6 participants with mild to moderate hypertension were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel C was 5 mg to 90 mg.	Panel D - MK-8150 50 to 200 mg n=5 Participants Description: Within Panel D, 8 healthy participants were randomly assigned to receive single doses of MK-8150, and 2 were randomly assigned to receive single administrations of matching placebo throughout the up to 5 treatment periods according to a computer-generated allocation schedule (i.e., assignment of a participant to either MK-8150 or placebo was fixed for all Panel D periods). This reporting group presents data for the Panel D participants administered MK-8150. The dose range of MK-8150 administered for Panel D was 50 mg to 200 mg.	Panel D - Placebo n=5 Participants Within Panel D, 8 healthy participants were randomly assigned to receive single doses of MK-8150, and 2 were randomly assigned to receive single administrations of matching placebo throughout the up to 5 treatment periods according to a computer-generated allocation schedule (i.e., assignment of a participant to either MK-8150 or placebo was fixed for all Panel D periods). This reporting group presents data for the Panel D participants administered placebo.	Panel A - Placebo n=8 Participants Single dose of placebo
Change From Baseline in TWA0-24hrs cSBP in Healthy Male Participants Administered Single Doses of MK-8150 and Placebo (Panel B)	-5.06 mm Hg Standard Error 0.91	-7.64 mm Hg Standard Error 1.50	-11.67 mm Hg Standard Error 1.68	-14.20 mm Hg Standard Error 1.60	-11.91 mm Hg Standard Error 1.26	-2.18 mm Hg Standard Error 1.11

PRIMARY outcome

Timeframe: Pre-dose and 2, 3, 4, 6, 8, 12, 16 and 24 hours post dose

Population: Per-Protocol population

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 2 to 90 mg/Placebo n=5 Participants Within each of the up to 5 treatment periods in Panel A, 6 healthy participants were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel A was 2 mg to 90 mg.	Panel B - MK-8150 4 to 120 mg/Placebo n=5 Participants Within each of the up to 5 treatment periods in Panel B, 6 healthy participants were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel B was 4 mg to 120 mg.	Panel C - MK-8150 5 to 90 mg/Placebo n=6 Participants Within each of the up to 5 treatment periods in Panel C, 6 participants with mild to moderate hypertension were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel C was 5 mg to 90 mg.	Panel D - MK-8150 50 to 200 mg n=6 Participants Description: Within Panel D, 8 healthy participants were randomly assigned to receive single doses of MK-8150, and 2 were randomly assigned to receive single administrations of matching placebo throughout the up to 5 treatment periods according to a computer-generated allocation schedule (i.e., assignment of a participant to either MK-8150 or placebo was fixed for all Panel D periods). This reporting group presents data for the Panel D participants administered MK-8150. The dose range of MK-8150 administered for Panel D was 50 mg to 200 mg.	Panel D - Placebo Within Panel D, 8 healthy participants were randomly assigned to receive single doses of MK-8150, and 2 were randomly assigned to receive single administrations of matching placebo throughout the up to 5 treatment periods according to a computer-generated allocation schedule (i.e., assignment of a participant to either MK-8150 or placebo was fixed for all Panel D periods). This reporting group presents data for the Panel D participants administered placebo.	Panel A - Placebo Single dose of placebo
Change From Baseline in TWA0-24hrs cSBP in Male Participants With Mild to Moderate Hypertension Administered Single Doses of MK-8150 and Placebo (Panel C)	-11.69 mm Hg Standard Error 3.01	-18.38 mm Hg Standard Error 4.47	-25.11 mm Hg Standard Error 3.20	-7.60 mm Hg Standard Error 4.46	—	—

PRIMARY outcome

Timeframe: Pre-dose and 2, 3, 4, 6, 8, 12, 16 and 24 hours post dose

Population: Per-Protocol population. The same 2 participants received placebo throughout all treatment periods of Panel D. Data for all administrations of placebo in these participants are included (i.e., for placebo, analysis includes 8 observations from 2 participants)

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 2 to 90 mg/Placebo n=8 Participants Within each of the up to 5 treatment periods in Panel A, 6 healthy participants were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel A was 2 mg to 90 mg.	Panel B - MK-8150 4 to 120 mg/Placebo n=8 Participants Within each of the up to 5 treatment periods in Panel B, 6 healthy participants were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel B was 4 mg to 120 mg.	Panel C - MK-8150 5 to 90 mg/Placebo n=8 Participants Within each of the up to 5 treatment periods in Panel C, 6 participants with mild to moderate hypertension were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel C was 5 mg to 90 mg.	Panel D - MK-8150 50 to 200 mg n=8 Participants Description: Within Panel D, 8 healthy participants were randomly assigned to receive single doses of MK-8150, and 2 were randomly assigned to receive single administrations of matching placebo throughout the up to 5 treatment periods according to a computer-generated allocation schedule (i.e., assignment of a participant to either MK-8150 or placebo was fixed for all Panel D periods). This reporting group presents data for the Panel D participants administered MK-8150. The dose range of MK-8150 administered for Panel D was 50 mg to 200 mg.	Panel D - Placebo n=2 Participants Within Panel D, 8 healthy participants were randomly assigned to receive single doses of MK-8150, and 2 were randomly assigned to receive single administrations of matching placebo throughout the up to 5 treatment periods according to a computer-generated allocation schedule (i.e., assignment of a participant to either MK-8150 or placebo was fixed for all Panel D periods). This reporting group presents data for the Panel D participants administered placebo.	Panel A - Placebo Single dose of placebo
Change From Baseline in TWA0-24hrs cSBP in Healthy Male Participants Administered Single Doses of MK-8150 and Placebo (Panel D)	-16.23 mm Hg Standard Error 1.40	-13.22 mm Hg Standard Error 1.55	-15.84 mm Hg Standard Error 1.50	-15.86 mm Hg Standard Error 1.47	-3.02 mm Hg Standard Error 0.38	—

PRIMARY outcome

Timeframe: Pre-dose and 2, 3, 4, 6, 8, 12, 16 and 24 hours post dose; except Period 1: Pre-dose and 2, 4, 12 and 24 hours post dose

AIx was measured by applanation tonometry of the radial artery, using the SphygmoCor System. The central pressure waveform was determined from the peripheral pressure waveform by a transfer function. Augmentation index is the percentage of the central pulse pressure attributed to the reflected pulse wave, and is an indirect measure of systemic arterial stiffness. Time-weighted average was obtained as follows: For all AIx values obtained over the 24-hour observation period, multiply the length of time that the participant spent at each AIx value by that AIx value, add these products together, and then divide by duration of the observation period. The length of time spent at an identified AIx value was defined as the time elapsed since previous post-dose measurement, or time elapsed since drug administration, if there is no previous post-dose measurement. AIx was adjusted for HR.

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 2 to 90 mg/Placebo n=6 Participants Within each of the up to 5 treatment periods in Panel A, 6 healthy participants were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel A was 2 mg to 90 mg.	Panel B - MK-8150 4 to 120 mg/Placebo n=6 Participants Within each of the up to 5 treatment periods in Panel B, 6 healthy participants were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel B was 4 mg to 120 mg.	Panel C - MK-8150 5 to 90 mg/Placebo n=6 Participants Within each of the up to 5 treatment periods in Panel C, 6 participants with mild to moderate hypertension were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel C was 5 mg to 90 mg.	Panel D - MK-8150 50 to 200 mg n=6 Participants Description: Within Panel D, 8 healthy participants were randomly assigned to receive single doses of MK-8150, and 2 were randomly assigned to receive single administrations of matching placebo throughout the up to 5 treatment periods according to a computer-generated allocation schedule (i.e., assignment of a participant to either MK-8150 or placebo was fixed for all Panel D periods). This reporting group presents data for the Panel D participants administered MK-8150. The dose range of MK-8150 administered for Panel D was 50 mg to 200 mg.	Panel D - Placebo n=6 Participants Within Panel D, 8 healthy participants were randomly assigned to receive single doses of MK-8150, and 2 were randomly assigned to receive single administrations of matching placebo throughout the up to 5 treatment periods according to a computer-generated allocation schedule (i.e., assignment of a participant to either MK-8150 or placebo was fixed for all Panel D periods). This reporting group presents data for the Panel D participants administered placebo.	Panel A - Placebo n=8 Participants Single dose of placebo
Change From Baseline in TWA0-24hrs AIx in Healthy Male Participants Administered Single Doses of MK-8150 and Placebo (Panel A)	-0.75 percentage of central pulse pressure Standard Error 1.99	-0.67 percentage of central pulse pressure Standard Error 1.63	-10.06 percentage of central pulse pressure Standard Error 1.62	-6.59 percentage of central pulse pressure Standard Error 2.22	-15.22 percentage of central pulse pressure Standard Error 1.53	1.56 percentage of central pulse pressure Standard Error 1.32

PRIMARY outcome

Timeframe: Pre-dose and 2, 3, 4, 6, 8, 12, 16 and 24 hours post dose

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 2 to 90 mg/Placebo n=6 Participants Within each of the up to 5 treatment periods in Panel A, 6 healthy participants were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel A was 2 mg to 90 mg.	Panel B - MK-8150 4 to 120 mg/Placebo n=6 Participants Within each of the up to 5 treatment periods in Panel B, 6 healthy participants were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel B was 4 mg to 120 mg.	Panel C - MK-8150 5 to 90 mg/Placebo n=6 Participants Within each of the up to 5 treatment periods in Panel C, 6 participants with mild to moderate hypertension were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel C was 5 mg to 90 mg.	Panel D - MK-8150 50 to 200 mg n=5 Participants Description: Within Panel D, 8 healthy participants were randomly assigned to receive single doses of MK-8150, and 2 were randomly assigned to receive single administrations of matching placebo throughout the up to 5 treatment periods according to a computer-generated allocation schedule (i.e., assignment of a participant to either MK-8150 or placebo was fixed for all Panel D periods). This reporting group presents data for the Panel D participants administered MK-8150. The dose range of MK-8150 administered for Panel D was 50 mg to 200 mg.	Panel D - Placebo n=5 Participants Within Panel D, 8 healthy participants were randomly assigned to receive single doses of MK-8150, and 2 were randomly assigned to receive single administrations of matching placebo throughout the up to 5 treatment periods according to a computer-generated allocation schedule (i.e., assignment of a participant to either MK-8150 or placebo was fixed for all Panel D periods). This reporting group presents data for the Panel D participants administered placebo.	Panel A - Placebo n=8 Participants Single dose of placebo
Change From Baseline in TWA0-24hrs AIx in Healthy Male Participants Administered Single Doses of MK-8150 and Placebo (Panel B)	-3.04 percentage of central pulse pressure Standard Error 1.55	-6.85 percentage of central pulse pressure Standard Error 1.83	-13.57 percentage of central pulse pressure Standard Error 2.54	-18.42 percentage of central pulse pressure Standard Error 1.55	-16.33 percentage of central pulse pressure Standard Error 2.22	-0.09 percentage of central pulse pressure Standard Error 1.50

PRIMARY outcome

Timeframe: Pre-dose and 2, 3, 4, 6, 8, 12, 16 and 24 hours post dose

Population: Per-Protocol population

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 2 to 90 mg/Placebo n=5 Participants Within each of the up to 5 treatment periods in Panel A, 6 healthy participants were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel A was 2 mg to 90 mg.	Panel B - MK-8150 4 to 120 mg/Placebo n=5 Participants Within each of the up to 5 treatment periods in Panel B, 6 healthy participants were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel B was 4 mg to 120 mg.	Panel C - MK-8150 5 to 90 mg/Placebo n=6 Participants Within each of the up to 5 treatment periods in Panel C, 6 participants with mild to moderate hypertension were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel C was 5 mg to 90 mg.	Panel D - MK-8150 50 to 200 mg n=6 Participants Description: Within Panel D, 8 healthy participants were randomly assigned to receive single doses of MK-8150, and 2 were randomly assigned to receive single administrations of matching placebo throughout the up to 5 treatment periods according to a computer-generated allocation schedule (i.e., assignment of a participant to either MK-8150 or placebo was fixed for all Panel D periods). This reporting group presents data for the Panel D participants administered MK-8150. The dose range of MK-8150 administered for Panel D was 50 mg to 200 mg.	Panel D - Placebo Within Panel D, 8 healthy participants were randomly assigned to receive single doses of MK-8150, and 2 were randomly assigned to receive single administrations of matching placebo throughout the up to 5 treatment periods according to a computer-generated allocation schedule (i.e., assignment of a participant to either MK-8150 or placebo was fixed for all Panel D periods). This reporting group presents data for the Panel D participants administered placebo.	Panel A - Placebo Single dose of placebo
Change From Baseline in TWA0-24hrs AIx in Male Participants With Mild to Moderate Hypertension Administered Single Doses of MK-8150 and Placebo (Panel C)	-8.32 percentage of central pulse pressure Standard Error 1.69	-12.09 percentage of central pulse pressure Standard Error 3.25	-21.03 percentage of central pulse pressure Standard Error 1.90	-6.73 percentage of central pulse pressure Standard Error 2.49	—	—

PRIMARY outcome

Timeframe: Pre-dose and 2, 3, 4, 6, 8, 12, 16 and 24 hours post dose

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 2 to 90 mg/Placebo n=8 Participants Within each of the up to 5 treatment periods in Panel A, 6 healthy participants were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel A was 2 mg to 90 mg.	Panel B - MK-8150 4 to 120 mg/Placebo n=8 Participants Within each of the up to 5 treatment periods in Panel B, 6 healthy participants were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel B was 4 mg to 120 mg.	Panel C - MK-8150 5 to 90 mg/Placebo n=8 Participants Within each of the up to 5 treatment periods in Panel C, 6 participants with mild to moderate hypertension were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel C was 5 mg to 90 mg.	Panel D - MK-8150 50 to 200 mg n=8 Participants Description: Within Panel D, 8 healthy participants were randomly assigned to receive single doses of MK-8150, and 2 were randomly assigned to receive single administrations of matching placebo throughout the up to 5 treatment periods according to a computer-generated allocation schedule (i.e., assignment of a participant to either MK-8150 or placebo was fixed for all Panel D periods). This reporting group presents data for the Panel D participants administered MK-8150. The dose range of MK-8150 administered for Panel D was 50 mg to 200 mg.	Panel D - Placebo n=2 Participants Within Panel D, 8 healthy participants were randomly assigned to receive single doses of MK-8150, and 2 were randomly assigned to receive single administrations of matching placebo throughout the up to 5 treatment periods according to a computer-generated allocation schedule (i.e., assignment of a participant to either MK-8150 or placebo was fixed for all Panel D periods). This reporting group presents data for the Panel D participants administered placebo.	Panel A - Placebo Single dose of placebo
Change From Baseline in TWA0-24hrs AIx in Healthy Male Participants Administered Single Doses of MK-8150 and Placebo (Panel D)	-13.83 percentage of central pulse pressure Standard Error 1.54	-12.04 percentage of central pulse pressure Standard Error 1.46	-15.09 percentage of central pulse pressure Standard Error 1.12	-14.42 percentage of central pulse pressure Standard Error 1.29	-1.46 percentage of central pulse pressure Standard Error 0.17	—

PRIMARY outcome

Timeframe: Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 9, 10, 11 and 12 hours post dose

HR was measured with a validated automatic measuring device. Time-weighted average was obtained as follows: For all HR values obtained over the 12-hour observation period, multiply the length of time that the participant spent at each HR value by that HR value, add these products together, and then divide by duration of the observation period. The length of time spent at an identified HR value was defined as the time elapsed since previous post-dose measurement, or time elapsed since drug administration, if there is no previous post-dose measurement.

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 2 to 90 mg/Placebo n=6 Participants Within each of the up to 5 treatment periods in Panel A, 6 healthy participants were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel A was 2 mg to 90 mg.	Panel B - MK-8150 4 to 120 mg/Placebo n=6 Participants Within each of the up to 5 treatment periods in Panel B, 6 healthy participants were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel B was 4 mg to 120 mg.	Panel C - MK-8150 5 to 90 mg/Placebo n=6 Participants Within each of the up to 5 treatment periods in Panel C, 6 participants with mild to moderate hypertension were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel C was 5 mg to 90 mg.	Panel D - MK-8150 50 to 200 mg n=6 Participants Description: Within Panel D, 8 healthy participants were randomly assigned to receive single doses of MK-8150, and 2 were randomly assigned to receive single administrations of matching placebo throughout the up to 5 treatment periods according to a computer-generated allocation schedule (i.e., assignment of a participant to either MK-8150 or placebo was fixed for all Panel D periods). This reporting group presents data for the Panel D participants administered MK-8150. The dose range of MK-8150 administered for Panel D was 50 mg to 200 mg.	Panel D - Placebo n=6 Participants Within Panel D, 8 healthy participants were randomly assigned to receive single doses of MK-8150, and 2 were randomly assigned to receive single administrations of matching placebo throughout the up to 5 treatment periods according to a computer-generated allocation schedule (i.e., assignment of a participant to either MK-8150 or placebo was fixed for all Panel D periods). This reporting group presents data for the Panel D participants administered placebo.	Panel A - Placebo n=8 Participants Single dose of placebo
Change From Baseline in Time-weighted Average Across 12 Hours (TWA0-12hrs) HR in Healthy Male Participants Administered Single Doses of MK-8150 and Placebo (Panel A)	2.94 beats per minute Standard Error 1.31	4.08 beats per minute Standard Error 1.61	4.07 beats per minute Standard Error 1.47	7.54 beats per minute Standard Error 2.19	4.04 beats per minute Standard Error 1.65	1.89 beats per minute Standard Error 1.43

PRIMARY outcome

Timeframe: Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 9, 10, 11 and 12 hours post dose

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 2 to 90 mg/Placebo n=6 Participants Within each of the up to 5 treatment periods in Panel A, 6 healthy participants were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel A was 2 mg to 90 mg.	Panel B - MK-8150 4 to 120 mg/Placebo n=6 Participants Within each of the up to 5 treatment periods in Panel B, 6 healthy participants were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel B was 4 mg to 120 mg.	Panel C - MK-8150 5 to 90 mg/Placebo n=6 Participants Within each of the up to 5 treatment periods in Panel C, 6 participants with mild to moderate hypertension were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel C was 5 mg to 90 mg.	Panel D - MK-8150 50 to 200 mg n=5 Participants Description: Within Panel D, 8 healthy participants were randomly assigned to receive single doses of MK-8150, and 2 were randomly assigned to receive single administrations of matching placebo throughout the up to 5 treatment periods according to a computer-generated allocation schedule (i.e., assignment of a participant to either MK-8150 or placebo was fixed for all Panel D periods). This reporting group presents data for the Panel D participants administered MK-8150. The dose range of MK-8150 administered for Panel D was 50 mg to 200 mg.	Panel D - Placebo n=5 Participants Within Panel D, 8 healthy participants were randomly assigned to receive single doses of MK-8150, and 2 were randomly assigned to receive single administrations of matching placebo throughout the up to 5 treatment periods according to a computer-generated allocation schedule (i.e., assignment of a participant to either MK-8150 or placebo was fixed for all Panel D periods). This reporting group presents data for the Panel D participants administered placebo.	Panel A - Placebo n=8 Participants Single dose of placebo
Change From Baseline in TWA0-12hrs HR in Healthy Male Participants Administered Single Doses of MK-8150 and Placebo (Panel B)	-0.26 beats per minute Standard Error 1.10	-0.91 beats per minute Standard Error 1.57	0.66 beats per minute Standard Error 1.75	3.17 beats per minute Standard Error 0.91	5.19 beats per minute Standard Error 1.45	0.57 beats per minute Standard Error 1.16

PRIMARY outcome

Timeframe: Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 9, 10, 11 and 12 hours post dose

Population: Per-Protocol population

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 2 to 90 mg/Placebo n=5 Participants Within each of the up to 5 treatment periods in Panel A, 6 healthy participants were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel A was 2 mg to 90 mg.	Panel B - MK-8150 4 to 120 mg/Placebo n=5 Participants Within each of the up to 5 treatment periods in Panel B, 6 healthy participants were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel B was 4 mg to 120 mg.	Panel C - MK-8150 5 to 90 mg/Placebo n=6 Participants Within each of the up to 5 treatment periods in Panel C, 6 participants with mild to moderate hypertension were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel C was 5 mg to 90 mg.	Panel D - MK-8150 50 to 200 mg n=6 Participants Description: Within Panel D, 8 healthy participants were randomly assigned to receive single doses of MK-8150, and 2 were randomly assigned to receive single administrations of matching placebo throughout the up to 5 treatment periods according to a computer-generated allocation schedule (i.e., assignment of a participant to either MK-8150 or placebo was fixed for all Panel D periods). This reporting group presents data for the Panel D participants administered MK-8150. The dose range of MK-8150 administered for Panel D was 50 mg to 200 mg.	Panel D - Placebo Within Panel D, 8 healthy participants were randomly assigned to receive single doses of MK-8150, and 2 were randomly assigned to receive single administrations of matching placebo throughout the up to 5 treatment periods according to a computer-generated allocation schedule (i.e., assignment of a participant to either MK-8150 or placebo was fixed for all Panel D periods). This reporting group presents data for the Panel D participants administered placebo.	Panel A - Placebo Single dose of placebo
Change From Baseline in TWA0-12hrs HR in Male Participants With Mild to Moderate Hypertension Administered Single Doses of MK-8150 and Placebo (Panel C)	-6.11 beats per minute Standard Error 2.32	-3.74 beats per minute Standard Error 1.58	-1.02 beats per minute Standard Error 1.75	-4.67 beats per minute Standard Error 2.23	—	—

PRIMARY outcome

Timeframe: Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 9, 10, 11 and 12 hours post dose

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 2 to 90 mg/Placebo n=8 Participants Within each of the up to 5 treatment periods in Panel A, 6 healthy participants were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel A was 2 mg to 90 mg.	Panel B - MK-8150 4 to 120 mg/Placebo n=8 Participants Within each of the up to 5 treatment periods in Panel B, 6 healthy participants were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel B was 4 mg to 120 mg.	Panel C - MK-8150 5 to 90 mg/Placebo n=8 Participants Within each of the up to 5 treatment periods in Panel C, 6 participants with mild to moderate hypertension were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel C was 5 mg to 90 mg.	Panel D - MK-8150 50 to 200 mg n=8 Participants Description: Within Panel D, 8 healthy participants were randomly assigned to receive single doses of MK-8150, and 2 were randomly assigned to receive single administrations of matching placebo throughout the up to 5 treatment periods according to a computer-generated allocation schedule (i.e., assignment of a participant to either MK-8150 or placebo was fixed for all Panel D periods). This reporting group presents data for the Panel D participants administered MK-8150. The dose range of MK-8150 administered for Panel D was 50 mg to 200 mg.	Panel D - Placebo n=2 Participants Within Panel D, 8 healthy participants were randomly assigned to receive single doses of MK-8150, and 2 were randomly assigned to receive single administrations of matching placebo throughout the up to 5 treatment periods according to a computer-generated allocation schedule (i.e., assignment of a participant to either MK-8150 or placebo was fixed for all Panel D periods). This reporting group presents data for the Panel D participants administered placebo.	Panel A - Placebo Single dose of placebo
Change From Baseline in TWA0-12hrs HR in Healthy Male Participants Administered Single Doses of MK-8150 and Placebo (Panel D)	-1.24 beats per minute Standard Error 1.90	-1.09 beats per minute Standard Error 2.15	-0.52 beats per minute Standard Error 1.59	3.83 beats per minute Standard Error 2.15	-5.67 beats per minute Standard Error 3.66	—

PRIMARY outcome

Timeframe: Pre-dose and 2, 3, 4, 6, 8, 12, 16 and 24 hours post dose

cDBP was measured by applanation tonometry of the radial artery, using the SphygmoCor System. The central pressure waveform was determined from the peripheral pressure waveform by a transfer function. Time-weighted average was obtained as follows: For all cDBP values obtained over the 24-hour observation period, multiply the length of time that the participant spent at each cDBP value by that cDBP value, add these products together, and then divide by duration of the observation period. The length of time spent at an identified cDBP value was defined as the time elapsed since previous post-dose measurement, or time elapsed since drug administration, if there is no previous post-dose measurement.

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 2 to 90 mg/Placebo n=6 Participants Within each of the up to 5 treatment periods in Panel A, 6 healthy participants were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel A was 2 mg to 90 mg.	Panel B - MK-8150 4 to 120 mg/Placebo n=6 Participants Within each of the up to 5 treatment periods in Panel B, 6 healthy participants were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel B was 4 mg to 120 mg.	Panel C - MK-8150 5 to 90 mg/Placebo n=6 Participants Within each of the up to 5 treatment periods in Panel C, 6 participants with mild to moderate hypertension were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel C was 5 mg to 90 mg.	Panel D - MK-8150 50 to 200 mg n=6 Participants Description: Within Panel D, 8 healthy participants were randomly assigned to receive single doses of MK-8150, and 2 were randomly assigned to receive single administrations of matching placebo throughout the up to 5 treatment periods according to a computer-generated allocation schedule (i.e., assignment of a participant to either MK-8150 or placebo was fixed for all Panel D periods). This reporting group presents data for the Panel D participants administered MK-8150. The dose range of MK-8150 administered for Panel D was 50 mg to 200 mg.	Panel D - Placebo n=6 Participants Within Panel D, 8 healthy participants were randomly assigned to receive single doses of MK-8150, and 2 were randomly assigned to receive single administrations of matching placebo throughout the up to 5 treatment periods according to a computer-generated allocation schedule (i.e., assignment of a participant to either MK-8150 or placebo was fixed for all Panel D periods). This reporting group presents data for the Panel D participants administered placebo.	Panel A - Placebo n=8 Participants Single dose of placebo
Change From Baseline in TWA0-24hrs cDBP in Healthy Male Participants Administered Single Doses of MK-8150 and Placebo (Panel A)	0.74 mm Hg Standard Error 1.07	-1.97 mm Hg Standard Error 1.46	-8.34 mm Hg Standard Error 1.77	-6.73 mm Hg Standard Error 2.27	-10.54 mm Hg Standard Error 1.62	-0.23 mm Hg Standard Error 1.11

PRIMARY outcome

Timeframe: Pre-dose and 2, 3, 4, 6, 8, 12, 16 and 24 hours post dose

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 2 to 90 mg/Placebo n=6 Participants Within each of the up to 5 treatment periods in Panel A, 6 healthy participants were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel A was 2 mg to 90 mg.	Panel B - MK-8150 4 to 120 mg/Placebo n=6 Participants Within each of the up to 5 treatment periods in Panel B, 6 healthy participants were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel B was 4 mg to 120 mg.	Panel C - MK-8150 5 to 90 mg/Placebo n=6 Participants Within each of the up to 5 treatment periods in Panel C, 6 participants with mild to moderate hypertension were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel C was 5 mg to 90 mg.	Panel D - MK-8150 50 to 200 mg n=5 Participants Description: Within Panel D, 8 healthy participants were randomly assigned to receive single doses of MK-8150, and 2 were randomly assigned to receive single administrations of matching placebo throughout the up to 5 treatment periods according to a computer-generated allocation schedule (i.e., assignment of a participant to either MK-8150 or placebo was fixed for all Panel D periods). This reporting group presents data for the Panel D participants administered MK-8150. The dose range of MK-8150 administered for Panel D was 50 mg to 200 mg.	Panel D - Placebo n=5 Participants Within Panel D, 8 healthy participants were randomly assigned to receive single doses of MK-8150, and 2 were randomly assigned to receive single administrations of matching placebo throughout the up to 5 treatment periods according to a computer-generated allocation schedule (i.e., assignment of a participant to either MK-8150 or placebo was fixed for all Panel D periods). This reporting group presents data for the Panel D participants administered placebo.	Panel A - Placebo n=8 Participants Single dose of placebo
Change From Baseline in TWA0-24hrs cDBP in Healthy Male Participants Administered Single Doses of MK-8150 and Placebo (Panel B)	-5.02 mm Hg Standard Error 1.10	-7.76 mm Hg Standard Error 1.61	-11.88 mm Hg Standard Error 1.75	-14.12 mm Hg Standard Error 1.95	-12.21 mm Hg Standard Error 1.30	-2.96 mm Hg Standard Error 1.33

PRIMARY outcome

Timeframe: Pre-dose and 2, 3, 4, 6, 8, 12, 16 and 24 hours post dose

Population: Per-Protocol population

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 2 to 90 mg/Placebo n=5 Participants Within each of the up to 5 treatment periods in Panel A, 6 healthy participants were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel A was 2 mg to 90 mg.	Panel B - MK-8150 4 to 120 mg/Placebo n=5 Participants Within each of the up to 5 treatment periods in Panel B, 6 healthy participants were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel B was 4 mg to 120 mg.	Panel C - MK-8150 5 to 90 mg/Placebo n=6 Participants Within each of the up to 5 treatment periods in Panel C, 6 participants with mild to moderate hypertension were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel C was 5 mg to 90 mg.	Panel D - MK-8150 50 to 200 mg n=6 Participants Description: Within Panel D, 8 healthy participants were randomly assigned to receive single doses of MK-8150, and 2 were randomly assigned to receive single administrations of matching placebo throughout the up to 5 treatment periods according to a computer-generated allocation schedule (i.e., assignment of a participant to either MK-8150 or placebo was fixed for all Panel D periods). This reporting group presents data for the Panel D participants administered MK-8150. The dose range of MK-8150 administered for Panel D was 50 mg to 200 mg.	Panel D - Placebo Within Panel D, 8 healthy participants were randomly assigned to receive single doses of MK-8150, and 2 were randomly assigned to receive single administrations of matching placebo throughout the up to 5 treatment periods according to a computer-generated allocation schedule (i.e., assignment of a participant to either MK-8150 or placebo was fixed for all Panel D periods). This reporting group presents data for the Panel D participants administered placebo.	Panel A - Placebo Single dose of placebo
Change From Baseline in TWA0-24hrs cDBP in Male Participants With Mild to Moderate Hypertension Administered Single Doses of MK-8150 and Placebo (Panel C)	-10.40 mm Hg Standard Error 1.96	-16.32 mm Hg Standard Error 3.97	-23.65 mm Hg Standard Error 2.67	-8.14 mm Hg Standard Error 3.76	—	—

PRIMARY outcome

Timeframe: Pre-dose and 2, 3, 4, 6, 8, 12, 16 and 24 hours post dose

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 2 to 90 mg/Placebo n=8 Participants Within each of the up to 5 treatment periods in Panel A, 6 healthy participants were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel A was 2 mg to 90 mg.	Panel B - MK-8150 4 to 120 mg/Placebo n=8 Participants Within each of the up to 5 treatment periods in Panel B, 6 healthy participants were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel B was 4 mg to 120 mg.	Panel C - MK-8150 5 to 90 mg/Placebo n=8 Participants Within each of the up to 5 treatment periods in Panel C, 6 participants with mild to moderate hypertension were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel C was 5 mg to 90 mg.	Panel D - MK-8150 50 to 200 mg n=8 Participants Description: Within Panel D, 8 healthy participants were randomly assigned to receive single doses of MK-8150, and 2 were randomly assigned to receive single administrations of matching placebo throughout the up to 5 treatment periods according to a computer-generated allocation schedule (i.e., assignment of a participant to either MK-8150 or placebo was fixed for all Panel D periods). This reporting group presents data for the Panel D participants administered MK-8150. The dose range of MK-8150 administered for Panel D was 50 mg to 200 mg.	Panel D - Placebo n=2 Participants Within Panel D, 8 healthy participants were randomly assigned to receive single doses of MK-8150, and 2 were randomly assigned to receive single administrations of matching placebo throughout the up to 5 treatment periods according to a computer-generated allocation schedule (i.e., assignment of a participant to either MK-8150 or placebo was fixed for all Panel D periods). This reporting group presents data for the Panel D participants administered placebo.	Panel A - Placebo Single dose of placebo
Change From Baseline in TWA0-24hrs cDBP in Healthy Male Participants Administered Single Doses of MK-8150 and Placebo (Panel D)	-15.55 mm Hg Standard Error 1.05	-13.26 mm Hg Standard Error 0.93	-15.35 mm Hg Standard Error 1.19	-15.84 mm Hg Standard Error 1.10	-4.71 mm Hg Standard Error 0.52	—

PRIMARY outcome

Timeframe: Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16 and 24 hours post dose

pSBP was measured with a validated automatic measuring device. Time-weighted average was obtained as follows: For all pSBP values obtained over the 24-hour observation period, multiply the length of time that the participant spent at each pSBP value by that pSBP value, add these products together, and then divide by duration of the observation period. The length of time spent at an identified pSBP value was defined as the time elapsed since previous post-dose measurement, or time elapsed since drug administration, if there is no previous post-dose measurement.

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 2 to 90 mg/Placebo n=6 Participants Within each of the up to 5 treatment periods in Panel A, 6 healthy participants were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel A was 2 mg to 90 mg.	Panel B - MK-8150 4 to 120 mg/Placebo n=6 Participants Within each of the up to 5 treatment periods in Panel B, 6 healthy participants were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel B was 4 mg to 120 mg.	Panel C - MK-8150 5 to 90 mg/Placebo n=6 Participants Within each of the up to 5 treatment periods in Panel C, 6 participants with mild to moderate hypertension were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel C was 5 mg to 90 mg.	Panel D - MK-8150 50 to 200 mg n=6 Participants Description: Within Panel D, 8 healthy participants were randomly assigned to receive single doses of MK-8150, and 2 were randomly assigned to receive single administrations of matching placebo throughout the up to 5 treatment periods according to a computer-generated allocation schedule (i.e., assignment of a participant to either MK-8150 or placebo was fixed for all Panel D periods). This reporting group presents data for the Panel D participants administered MK-8150. The dose range of MK-8150 administered for Panel D was 50 mg to 200 mg.	Panel D - Placebo n=6 Participants Within Panel D, 8 healthy participants were randomly assigned to receive single doses of MK-8150, and 2 were randomly assigned to receive single administrations of matching placebo throughout the up to 5 treatment periods according to a computer-generated allocation schedule (i.e., assignment of a participant to either MK-8150 or placebo was fixed for all Panel D periods). This reporting group presents data for the Panel D participants administered placebo.	Panel A - Placebo n=8 Participants Single dose of placebo
Change From Baseline in TWA0-24hrs pSBP in Healthy Male Participants Administered Single Doses of MK-8150 and Placebo (Panel A)	0.73 mm Hg Standard Error 1.35	-0.24 mm Hg Standard Error 1.45	-3.13 mm Hg Standard Error 1.56	-1.91 mm Hg Standard Error 1.42	-4.46 mm Hg Standard Error 1.70	1.46 mm Hg Standard Error 1.41

PRIMARY outcome

Timeframe: Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16 and 24 hours post dose

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 2 to 90 mg/Placebo n=6 Participants Within each of the up to 5 treatment periods in Panel A, 6 healthy participants were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel A was 2 mg to 90 mg.	Panel B - MK-8150 4 to 120 mg/Placebo n=6 Participants Within each of the up to 5 treatment periods in Panel B, 6 healthy participants were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel B was 4 mg to 120 mg.	Panel C - MK-8150 5 to 90 mg/Placebo n=6 Participants Within each of the up to 5 treatment periods in Panel C, 6 participants with mild to moderate hypertension were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel C was 5 mg to 90 mg.	Panel D - MK-8150 50 to 200 mg n=5 Participants Description: Within Panel D, 8 healthy participants were randomly assigned to receive single doses of MK-8150, and 2 were randomly assigned to receive single administrations of matching placebo throughout the up to 5 treatment periods according to a computer-generated allocation schedule (i.e., assignment of a participant to either MK-8150 or placebo was fixed for all Panel D periods). This reporting group presents data for the Panel D participants administered MK-8150. The dose range of MK-8150 administered for Panel D was 50 mg to 200 mg.	Panel D - Placebo n=5 Participants Within Panel D, 8 healthy participants were randomly assigned to receive single doses of MK-8150, and 2 were randomly assigned to receive single administrations of matching placebo throughout the up to 5 treatment periods according to a computer-generated allocation schedule (i.e., assignment of a participant to either MK-8150 or placebo was fixed for all Panel D periods). This reporting group presents data for the Panel D participants administered placebo.	Panel A - Placebo n=8 Participants Single dose of placebo
Change From Baseline in TWA0-24hrs pSBP in Healthy Male Participants Administered Single Doses of MK-8150 and Placebo (Panel B)	-4.61 mm Hg Standard Error 1.00	-6.81 mm Hg Standard Error 1.61	-7.16 mm Hg Standard Error 2.00	-8.50 mm Hg Standard Error 1.39	-6.40 mm Hg Standard Error 1.19	-1.17 mm Hg Standard Error 1.01

PRIMARY outcome

Timeframe: Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16 and 24 hours post dose

Population: Per-Protocol population

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 2 to 90 mg/Placebo n=5 Participants Within each of the up to 5 treatment periods in Panel A, 6 healthy participants were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel A was 2 mg to 90 mg.	Panel B - MK-8150 4 to 120 mg/Placebo n=5 Participants Within each of the up to 5 treatment periods in Panel B, 6 healthy participants were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel B was 4 mg to 120 mg.	Panel C - MK-8150 5 to 90 mg/Placebo n=6 Participants Within each of the up to 5 treatment periods in Panel C, 6 participants with mild to moderate hypertension were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel C was 5 mg to 90 mg.	Panel D - MK-8150 50 to 200 mg n=6 Participants Description: Within Panel D, 8 healthy participants were randomly assigned to receive single doses of MK-8150, and 2 were randomly assigned to receive single administrations of matching placebo throughout the up to 5 treatment periods according to a computer-generated allocation schedule (i.e., assignment of a participant to either MK-8150 or placebo was fixed for all Panel D periods). This reporting group presents data for the Panel D participants administered MK-8150. The dose range of MK-8150 administered for Panel D was 50 mg to 200 mg.	Panel D - Placebo Within Panel D, 8 healthy participants were randomly assigned to receive single doses of MK-8150, and 2 were randomly assigned to receive single administrations of matching placebo throughout the up to 5 treatment periods according to a computer-generated allocation schedule (i.e., assignment of a participant to either MK-8150 or placebo was fixed for all Panel D periods). This reporting group presents data for the Panel D participants administered placebo.	Panel A - Placebo Single dose of placebo
Change From Baseline in TWA0-24hrs pSBP in Male Participants With Mild to Moderate Hypertension Administered Single Doses of MK-8150 and Placebo (Panel C)	-12.32 mm Hg Standard Error 3.88	-18.26 mm Hg Standard Error 4.84	-21.42 mm Hg Standard Error 3.63	-5.39 mm Hg Standard Error 6.63	—	—

PRIMARY outcome

Timeframe: Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16 and 24 hours post dose

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 2 to 90 mg/Placebo n=8 Participants Within each of the up to 5 treatment periods in Panel A, 6 healthy participants were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel A was 2 mg to 90 mg.	Panel B - MK-8150 4 to 120 mg/Placebo n=8 Participants Within each of the up to 5 treatment periods in Panel B, 6 healthy participants were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel B was 4 mg to 120 mg.	Panel C - MK-8150 5 to 90 mg/Placebo n=8 Participants Within each of the up to 5 treatment periods in Panel C, 6 participants with mild to moderate hypertension were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel C was 5 mg to 90 mg.	Panel D - MK-8150 50 to 200 mg n=8 Participants Description: Within Panel D, 8 healthy participants were randomly assigned to receive single doses of MK-8150, and 2 were randomly assigned to receive single administrations of matching placebo throughout the up to 5 treatment periods according to a computer-generated allocation schedule (i.e., assignment of a participant to either MK-8150 or placebo was fixed for all Panel D periods). This reporting group presents data for the Panel D participants administered MK-8150. The dose range of MK-8150 administered for Panel D was 50 mg to 200 mg.	Panel D - Placebo n=2 Participants Within Panel D, 8 healthy participants were randomly assigned to receive single doses of MK-8150, and 2 were randomly assigned to receive single administrations of matching placebo throughout the up to 5 treatment periods according to a computer-generated allocation schedule (i.e., assignment of a participant to either MK-8150 or placebo was fixed for all Panel D periods). This reporting group presents data for the Panel D participants administered placebo.	Panel A - Placebo Single dose of placebo
Change From Baseline in TWA0-24hrs pSBP in Healthy Male Participants Administered Single Doses of MK-8150 and Placebo (Panel D)	-12.77 mm Hg Standard Error 1.14	-10.19 mm Hg Standard Error 1.86	-11.19 mm Hg Standard Error 1.78	-10.47 mm Hg Standard Error 1.79	-3.00 mm Hg Standard Error 0.85	—

PRIMARY outcome

Timeframe: Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16 and 24 hours post dose

pDBP was measured with a validated automatic measuring device. Time-weighted average was obtained as follows: For all pDBP values obtained over the 24-hour observation period, multiply the length of time that the participant spent at each pDBP value by that pDBP value, add these products together, and then divide by duration of the observation period. The length of time spent at an identified pDBP value was defined as the time elapsed since previous post-dose measurement, or time elapsed since drug administration, if there is no previous post-dose measurement.

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 2 to 90 mg/Placebo n=6 Participants Within each of the up to 5 treatment periods in Panel A, 6 healthy participants were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel A was 2 mg to 90 mg.	Panel B - MK-8150 4 to 120 mg/Placebo n=6 Participants Within each of the up to 5 treatment periods in Panel B, 6 healthy participants were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel B was 4 mg to 120 mg.	Panel C - MK-8150 5 to 90 mg/Placebo n=6 Participants Within each of the up to 5 treatment periods in Panel C, 6 participants with mild to moderate hypertension were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel C was 5 mg to 90 mg.	Panel D - MK-8150 50 to 200 mg n=6 Participants Description: Within Panel D, 8 healthy participants were randomly assigned to receive single doses of MK-8150, and 2 were randomly assigned to receive single administrations of matching placebo throughout the up to 5 treatment periods according to a computer-generated allocation schedule (i.e., assignment of a participant to either MK-8150 or placebo was fixed for all Panel D periods). This reporting group presents data for the Panel D participants administered MK-8150. The dose range of MK-8150 administered for Panel D was 50 mg to 200 mg.	Panel D - Placebo n=6 Participants Within Panel D, 8 healthy participants were randomly assigned to receive single doses of MK-8150, and 2 were randomly assigned to receive single administrations of matching placebo throughout the up to 5 treatment periods according to a computer-generated allocation schedule (i.e., assignment of a participant to either MK-8150 or placebo was fixed for all Panel D periods). This reporting group presents data for the Panel D participants administered placebo.	Panel A - Placebo n=8 Participants Single dose of placebo
Change From Baseline in TWA0-24hrs pDBP in Healthy Male Participants Administered Single Doses of MK-8150 and Placebo (Panel A)	-0.92 mm Hg Standard Error 0.61	-2.58 mm Hg Standard Error 1.13	-8.01 mm Hg Standard Error 1.56	-6.69 mm Hg Standard Error 2.30	-9.85 mm Hg Standard Error 1.38	-1.24 mm Hg Standard Error 0.90

PRIMARY outcome

Timeframe: Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16 and 24 hours post dose

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 2 to 90 mg/Placebo n=6 Participants Within each of the up to 5 treatment periods in Panel A, 6 healthy participants were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel A was 2 mg to 90 mg.	Panel B - MK-8150 4 to 120 mg/Placebo n=6 Participants Within each of the up to 5 treatment periods in Panel B, 6 healthy participants were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel B was 4 mg to 120 mg.	Panel C - MK-8150 5 to 90 mg/Placebo n=6 Participants Within each of the up to 5 treatment periods in Panel C, 6 participants with mild to moderate hypertension were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel C was 5 mg to 90 mg.	Panel D - MK-8150 50 to 200 mg n=5 Participants Description: Within Panel D, 8 healthy participants were randomly assigned to receive single doses of MK-8150, and 2 were randomly assigned to receive single administrations of matching placebo throughout the up to 5 treatment periods according to a computer-generated allocation schedule (i.e., assignment of a participant to either MK-8150 or placebo was fixed for all Panel D periods). This reporting group presents data for the Panel D participants administered MK-8150. The dose range of MK-8150 administered for Panel D was 50 mg to 200 mg.	Panel D - Placebo n=5 Participants Within Panel D, 8 healthy participants were randomly assigned to receive single doses of MK-8150, and 2 were randomly assigned to receive single administrations of matching placebo throughout the up to 5 treatment periods according to a computer-generated allocation schedule (i.e., assignment of a participant to either MK-8150 or placebo was fixed for all Panel D periods). This reporting group presents data for the Panel D participants administered placebo.	Panel A - Placebo n=8 Participants Single dose of placebo
Change From Baseline in TWA0-24hrs pDBP in Healthy Male Participants Administered Single Doses of MK-8150 and Placebo (Panel B)	-3.91 mm Hg Standard Error 1.02	-6.21 mm Hg Standard Error 1.34	-9.64 mm Hg Standard Error 1.86	-11.69 mm Hg Standard Error 1.85	-10.20 mm Hg Standard Error 1.11	-1.90 mm Hg Standard Error 0.85

PRIMARY outcome

Timeframe: Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16 and 24 hours post dose

Population: Per-Protocol population

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 2 to 90 mg/Placebo n=5 Participants Within each of the up to 5 treatment periods in Panel A, 6 healthy participants were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel A was 2 mg to 90 mg.	Panel B - MK-8150 4 to 120 mg/Placebo n=5 Participants Within each of the up to 5 treatment periods in Panel B, 6 healthy participants were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel B was 4 mg to 120 mg.	Panel C - MK-8150 5 to 90 mg/Placebo n=6 Participants Within each of the up to 5 treatment periods in Panel C, 6 participants with mild to moderate hypertension were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel C was 5 mg to 90 mg.	Panel D - MK-8150 50 to 200 mg n=6 Participants Description: Within Panel D, 8 healthy participants were randomly assigned to receive single doses of MK-8150, and 2 were randomly assigned to receive single administrations of matching placebo throughout the up to 5 treatment periods according to a computer-generated allocation schedule (i.e., assignment of a participant to either MK-8150 or placebo was fixed for all Panel D periods). This reporting group presents data for the Panel D participants administered MK-8150. The dose range of MK-8150 administered for Panel D was 50 mg to 200 mg.	Panel D - Placebo Within Panel D, 8 healthy participants were randomly assigned to receive single doses of MK-8150, and 2 were randomly assigned to receive single administrations of matching placebo throughout the up to 5 treatment periods according to a computer-generated allocation schedule (i.e., assignment of a participant to either MK-8150 or placebo was fixed for all Panel D periods). This reporting group presents data for the Panel D participants administered placebo.	Panel A - Placebo Single dose of placebo
Change From Baseline in TWA0-24hrs pDBP in Male Participants With Mild to Moderate Hypertension Administered Single Doses of MK-8150 and Placebo (Panel C)	-7.87 mm Hg Standard Error 1.89	-12.90 mm Hg Standard Error 3.55	-19.82 mm Hg Standard Error 2.27	-6.14 mm Hg Standard Error 3.80	—	—

PRIMARY outcome

Timeframe: Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16 and 24 hours post dose

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 2 to 90 mg/Placebo n=8 Participants Within each of the up to 5 treatment periods in Panel A, 6 healthy participants were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel A was 2 mg to 90 mg.	Panel B - MK-8150 4 to 120 mg/Placebo n=8 Participants Within each of the up to 5 treatment periods in Panel B, 6 healthy participants were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel B was 4 mg to 120 mg.	Panel C - MK-8150 5 to 90 mg/Placebo n=8 Participants Within each of the up to 5 treatment periods in Panel C, 6 participants with mild to moderate hypertension were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel C was 5 mg to 90 mg.	Panel D - MK-8150 50 to 200 mg n=8 Participants Description: Within Panel D, 8 healthy participants were randomly assigned to receive single doses of MK-8150, and 2 were randomly assigned to receive single administrations of matching placebo throughout the up to 5 treatment periods according to a computer-generated allocation schedule (i.e., assignment of a participant to either MK-8150 or placebo was fixed for all Panel D periods). This reporting group presents data for the Panel D participants administered MK-8150. The dose range of MK-8150 administered for Panel D was 50 mg to 200 mg.	Panel D - Placebo n=2 Participants Within Panel D, 8 healthy participants were randomly assigned to receive single doses of MK-8150, and 2 were randomly assigned to receive single administrations of matching placebo throughout the up to 5 treatment periods according to a computer-generated allocation schedule (i.e., assignment of a participant to either MK-8150 or placebo was fixed for all Panel D periods). This reporting group presents data for the Panel D participants administered placebo.	Panel A - Placebo Single dose of placebo
Change From Baseline in TWA0-24hrs pDBP in Healthy Male Participants Administered Single Doses of MK-8150 and Placebo (Panel D)	-13.91 mm Hg Standard Error 0.77	-11.65 mm Hg Standard Error 0.61	-13.36 mm Hg Standard Error 0.87	-14.31 mm Hg Standard Error 0.87	-4.79 mm Hg Standard Error 1.17	—

Adverse Events

Panel A - MK-8150 2 to 90 mg/Placebo

Serious events: 0 serious events

Other events: 8 other events

Deaths: 0 deaths

Panel B - MK-8150 4 to 120 mg/Placebo

Serious events: 0 serious events

Other events: 8 other events

Deaths: 0 deaths

Panel C - MK-8150 5 to 90 mg/Placebo

Serious events: 0 serious events

Other events: 7 other events

Deaths: 0 deaths

Panel D - MK-8150 50 to 200 mg

Serious events: 0 serious events

Other events: 7 other events

Deaths: 0 deaths

Panel D - Placebo

Serious events: 0 serious events

Other events: 2 other events

Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure	Panel A - MK-8150 2 to 90 mg/Placebo n=8 participants at risk Within each of the up to 5 treatment periods in Panel A, 6 healthy participants were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel A was 2 mg to 90 mg.	Panel B - MK-8150 4 to 120 mg/Placebo n=8 participants at risk Within each of the up to 5 treatment periods in Panel B, 6 healthy participants were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel B was 4 mg to 120 mg.	Panel C - MK-8150 5 to 90 mg/Placebo n=8 participants at risk Within each of the up to 5 treatment periods in Panel C, 6 participants with mild to moderate hypertension were randomly assigned to receive a single dose of MK-8150, and 2 were randomly assigned to receive single administration of matching placebo according to a computer-generated allocation schedule. By protocol allocation schedule participants did not have fixed assignment to single dose MK-8150 or placebo for all treatment periods, but were reallocated from one treatment period to the next, so that a participant could receive both MK-8150 and placebo, in different periods of the Panel. The dose range of MK-8150 administered for Panel C was 5 mg to 90 mg.	Panel D - MK-8150 50 to 200 mg n=8 participants at risk Within Panel D, 8 healthy participants were randomly assigned to receive single doses of MK-8150, and 2 were randomly assigned to receive single administrations of matching placebo throughout the up to 5 treatment periods according to a computer-generated allocation schedule (i.e., assignment of a participant to either MK-8150 or placebo was fixed for all Panel D periods). This reporting group presents data for the Panel D participants administered MK-8150. The dose range of MK-8150 administered for Panel D was 50 mg to 200 mg.	Panel D - Placebo n=2 participants at risk Within Panel D, 8 healthy participants were randomly assigned to receive single doses of MK-8150, and 2 were randomly assigned to receive single administrations of matching placebo throughout the up to 5 treatment periods according to a computer-generated allocation schedule (i.e., assignment of a participant to either MK-8150 or placebo was fixed for all Panel D periods). This reporting group presents data for the Panel D participants administered placebo.
Cardiac disorders Palpitations	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	25.0% 2/8 • Number of events 6 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	25.0% 2/8 • Number of events 2 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/2 • Up to 14 days after the last dose (Up to approximately 42 days)
Cardiac disorders Postural orthostatic tachycardia syndrome	12.5% 1/8 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days)	12.5% 1/8 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	12.5% 1/8 • Number of events 2 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/2 • Up to 14 days after the last dose (Up to approximately 42 days)
Eye disorders Conjunctivitis	12.5% 1/8 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/2 • Up to 14 days after the last dose (Up to approximately 42 days)
Gastrointestinal disorders Constipation	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	12.5% 1/8 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/2 • Up to 14 days after the last dose (Up to approximately 42 days)
Gastrointestinal disorders Diarrhoea	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	25.0% 2/8 • Number of events 2 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/2 • Up to 14 days after the last dose (Up to approximately 42 days)
Gastrointestinal disorders Loose stools	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	12.5% 1/8 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/2 • Up to 14 days after the last dose (Up to approximately 42 days)
Gastrointestinal disorders Nausea	12.5% 1/8 • Number of events 2 • Up to 14 days after the last dose (Up to approximately 42 days)	25.0% 2/8 • Number of events 4 • Up to 14 days after the last dose (Up to approximately 42 days)	37.5% 3/8 • Number of events 5 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/2 • Up to 14 days after the last dose (Up to approximately 42 days)
Gastrointestinal disorders Regurgitation	12.5% 1/8 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/2 • Up to 14 days after the last dose (Up to approximately 42 days)
General disorders Application site pruritus	12.5% 1/8 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/2 • Up to 14 days after the last dose (Up to approximately 42 days)
General disorders Chest discomfort	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	12.5% 1/8 • Number of events 3 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/2 • Up to 14 days after the last dose (Up to approximately 42 days)
General disorders Fatigue	50.0% 4/8 • Number of events 5 • Up to 14 days after the last dose (Up to approximately 42 days)	12.5% 1/8 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	12.5% 1/8 • Number of events 2 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/2 • Up to 14 days after the last dose (Up to approximately 42 days)
General disorders Feeling cold	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	12.5% 1/8 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/2 • Up to 14 days after the last dose (Up to approximately 42 days)
Infections and infestations Common cold	12.5% 1/8 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	12.5% 1/8 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days)	12.5% 1/8 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/2 • Up to 14 days after the last dose (Up to approximately 42 days)
Infections and infestations Folliculitis	12.5% 1/8 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/2 • Up to 14 days after the last dose (Up to approximately 42 days)
Infections and infestations Herpes zoster	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	50.0% 1/2 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days)
Injury, poisoning and procedural complications Laceration of finger	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	12.5% 1/8 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/2 • Up to 14 days after the last dose (Up to approximately 42 days)
Injury, poisoning and procedural complications Procedural pain	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	12.5% 1/8 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/2 • Up to 14 days after the last dose (Up to approximately 42 days)
Investigations Neutrophil count increased	12.5% 1/8 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/2 • Up to 14 days after the last dose (Up to approximately 42 days)
Investigations Orthostatic heart rate response increased	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	12.5% 1/8 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/2 • Up to 14 days after the last dose (Up to approximately 42 days)
Investigations Red blood cells urine positive	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	12.5% 1/8 • Number of events 4 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/2 • Up to 14 days after the last dose (Up to approximately 42 days)
Investigations White blood cell count increased	12.5% 1/8 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/2 • Up to 14 days after the last dose (Up to approximately 42 days)
Investigations White blood cells urine increased	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	12.5% 1/8 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/2 • Up to 14 days after the last dose (Up to approximately 42 days)
Musculoskeletal and connective tissue disorders Bone pain	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	12.5% 1/8 • Number of events 2 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/2 • Up to 14 days after the last dose (Up to approximately 42 days)
Musculoskeletal and connective tissue disorders Musculoskeletal chest pain	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	12.5% 1/8 • Number of events 3 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/2 • Up to 14 days after the last dose (Up to approximately 42 days)
Musculoskeletal and connective tissue disorders Musculoskeletal pain	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	12.5% 1/8 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/2 • Up to 14 days after the last dose (Up to approximately 42 days)
Musculoskeletal and connective tissue disorders Myalgia	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	12.5% 1/8 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/2 • Up to 14 days after the last dose (Up to approximately 42 days)
Musculoskeletal and connective tissue disorders Myalgia of lower extremities	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	12.5% 1/8 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/2 • Up to 14 days after the last dose (Up to approximately 42 days)
Musculoskeletal and connective tissue disorders Neck pain	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	12.5% 1/8 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days)	12.5% 1/8 • Number of events 2 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	50.0% 1/2 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days)
Musculoskeletal and connective tissue disorders Pain ankle	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	12.5% 1/8 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/2 • Up to 14 days after the last dose (Up to approximately 42 days)
Musculoskeletal and connective tissue disorders Pain in elbow	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	50.0% 1/2 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days)
Musculoskeletal and connective tissue disorders Shoulder pain	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	50.0% 1/2 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days)
Nervous system disorders Dizziness	12.5% 1/8 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days)	12.5% 1/8 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	25.0% 2/8 • Number of events 3 • Up to 14 days after the last dose (Up to approximately 42 days)	50.0% 1/2 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days)
Nervous system disorders Dizziness postural	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	12.5% 1/8 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	12.5% 1/8 • Number of events 2 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/2 • Up to 14 days after the last dose (Up to approximately 42 days)
Nervous system disorders Headache	75.0% 6/8 • Number of events 19 • Up to 14 days after the last dose (Up to approximately 42 days)	87.5% 7/8 • Number of events 37 • Up to 14 days after the last dose (Up to approximately 42 days)	75.0% 6/8 • Number of events 10 • Up to 14 days after the last dose (Up to approximately 42 days)	87.5% 7/8 • Number of events 28 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/2 • Up to 14 days after the last dose (Up to approximately 42 days)
Nervous system disorders Presyncope	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	12.5% 1/8 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/2 • Up to 14 days after the last dose (Up to approximately 42 days)
Nervous system disorders Somnolence	12.5% 1/8 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days)	12.5% 1/8 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/2 • Up to 14 days after the last dose (Up to approximately 42 days)
Nervous system disorders Syncope	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	50.0% 1/2 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days)
Psychiatric disorders Insomnia	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	12.5% 1/8 • Number of events 2 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/2 • Up to 14 days after the last dose (Up to approximately 42 days)
Psychiatric disorders Nervousness	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	12.5% 1/8 • Number of events 3 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/2 • Up to 14 days after the last dose (Up to approximately 42 days)
Renal and urinary disorders Haematuria	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	12.5% 1/8 • Number of events 2 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/2 • Up to 14 days after the last dose (Up to approximately 42 days)
Renal and urinary disorders Polyuria	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	12.5% 1/8 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/2 • Up to 14 days after the last dose (Up to approximately 42 days)
Respiratory, thoracic and mediastinal disorders Cough	12.5% 1/8 • Number of events 2 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/2 • Up to 14 days after the last dose (Up to approximately 42 days)
Respiratory, thoracic and mediastinal disorders Epistaxis	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	12.5% 1/8 • Number of events 2 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	12.5% 1/8 • Number of events 4 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/2 • Up to 14 days after the last dose (Up to approximately 42 days)
Respiratory, thoracic and mediastinal disorders Oropharyngeal discomfort	12.5% 1/8 • Number of events 2 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/2 • Up to 14 days after the last dose (Up to approximately 42 days)
Skin and subcutaneous tissue disorders Cold sweat	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	12.5% 1/8 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/2 • Up to 14 days after the last dose (Up to approximately 42 days)
Skin and subcutaneous tissue disorders Rash maculo-papular	12.5% 1/8 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/2 • Up to 14 days after the last dose (Up to approximately 42 days)
Skin and subcutaneous tissue disorders Skin exfoliation	12.5% 1/8 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/2 • Up to 14 days after the last dose (Up to approximately 42 days)
Vascular disorders Diastolic hypertension	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	12.5% 1/8 • Number of events 3 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/2 • Up to 14 days after the last dose (Up to approximately 42 days)
Vascular disorders Haematoma	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	12.5% 1/8 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/2 • Up to 14 days after the last dose (Up to approximately 42 days)
Vascular disorders Hot flushes facial	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	12.5% 1/8 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/2 • Up to 14 days after the last dose (Up to approximately 42 days)
Vascular disorders Orthostatic hypotension	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	12.5% 1/8 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days)	12.5% 1/8 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days)	12.5% 1/8 • Number of events 3 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/2 • Up to 14 days after the last dose (Up to approximately 42 days)
Vascular disorders Systolic hypertension	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	12.5% 1/8 • Number of events 9 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days)	0.00% 0/2 • Up to 14 days after the last dose (Up to approximately 42 days)

Additional Information

Senior Vice President, Global Clinical Development

Merck Sharp & Dohme Corp.

Phone: 1-800-672-6372

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication timelines.
Publication restrictions are in place

Restriction type: OTHER